In summary, these data show that the combination of allosteric inhibition and Dasatinib overcomes the resistance in primary PDLTCs from Ph + ALL patients harboring the BCR/ABL-T315I mutation. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.